An example of such a personalized approach is the well-known drug trastuzumab, which was approved years ago for the treatment of HER2 receptor positive breast cancer [38], but also the promising use of the poly-ADP ribose polymerase inhibitor olaparib in the treatment of BRCA-mutant ovarian cancer [39]. The gene discussed is ERBB2; the disease is ovarian cancer.